Column
You can view the research column published every month by SMC Laboratories.
2024.03.15
[Existing compounds] that have advanced to clinical trials will accelerate the launch of your drugs.
If you are planning to launch your therapeutic drug, you should select disease mouse models that have shown action and efficacy in the same pathway and have progressed to the clinical trial. The reason being that although there are many potential therapeutic targets for MASH/NASH, there are currently no approved drugs for the treatment of…
READ MORE
2024.03.15
Pitfalls of [ disease model mice ] that researchers unknowingly fall into.
In order to evaluate your compound, rather than using a general pulmonary fibrosis model that does not match your pathology, you should use one that allows you to successfully evaluate your desired pathologies. We have seen some cases where this has not been achieved. The bleomycin-induced pulmonary fibrosis model is commonly used to reproduce the…
READ MORE
2024.03.15
| A must for IPF researchers! | Suggestions for the best disease model for your research
If you are considering a drug efficacy study using a mouse model of lung fibrosis, you should use a model that best suits your purpose, rather than a generic study design for that model. The bleomycin-induced lung fibrosis model is widely used for drug efficacy studies, and the general study design for it is publicly…
READ MORE
Page 14 of 14First<<1011121314
